STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Avidity Group Reports 5,615,811 Shares (5.9%) in Immunic IMUX

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Avidity-related reporting persons disclosed an aggregate 5,615,811 share position in Immunic, Inc. (IMUX), equal to 5.9% of the outstanding common stock, held with shared voting and dispositive power. The filing shows no reporting person claims sole voting or dispositive authority over these shares. A separate entity, Avidity Private Master Fund I LP, is shown with 4,699,411 shares (4.9%).

The statement explains the reported securities are directly owned by advisory clients of Avidity Partners Management LP and that none of those advisory clients may be deemed to beneficially own more than 5% of the class. The reporting persons include a disclaimer of beneficial ownership except to the extent of pecuniary interest and certify the holdings were not acquired to change or influence control of the issuer.

Positive

  • Avidity group reports a material institutional stake of 5,615,811 shares (5.9%) in Immunic (IMUX)
  • Avidity Private Master Fund I LP holds 4,699,411 shares (4.9%), showing substantial related-party investment
  • Filing includes certification that the holdings were not acquired to change or influence control of the issuer

Negative

  • No reporting person has sole voting or dispositive power; all authority is reported as shared
  • Securities are directly owned by advisory clients, and the filing states none of those clients may be deemed to beneficially own more than 5% individually, complicating ownership attribution
  • Reporting persons disclaim beneficial ownership except to the extent of pecuniary interest, limiting clarity on control implications

Insights

TL;DR: Avidity reports a material institutional stake of 5.9% in IMUX, but power is shared and holdings are held for advisory clients, limiting direct control.

The filing discloses an aggregate 5,615,811 share position (5.9%) across Avidity entities with only shared voting and dispositive power and no sole authority. That size typically requires disclosure and signals meaningful economic exposure, but the statement that securities are directly owned by advisory clients and that none of those clients individually exceed 5% reduces the likelihood that any single client or Avidity itself exercises unilateral control. The certification that holdings were not acquired to influence control further frames this as a passive/investment disclosure rather than an activist intent.Impact rating: 0

TL;DR: The structure and disclaimers indicate presence of a substantial stake without a clear change in governance influence.

The report makes clear that multiple affiliated entities and an individual (Michael Gregory) are reporting the position, and that all reported shares reflect shared voting and dispositive power. Item 6 and the signature comments explicitly state the securities are held for advisory clients and disclaim broader beneficial ownership, which is important for interpreting whether the filing creates a control narrative. From a governance perspective, the combination of a >5% aggregate holding and explicit disclaimers suggests monitoring by investors and issuers but not an immediate corporate-control action.Impact rating: 0






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Avidity Partners Management LP
Signature:By: Avidity Partners Management (GP) LLC, its general partner, By: /s/ Michael Gregory
Name/Title:Michael Gregory/Managing Member
Date:08/14/2025
Avidity Partners Management (GP) LLC
Signature:/s/ Michael Gregory
Name/Title:Michael Gregory/Managing Member
Date:08/14/2025
Avidity Capital Partners Fund (GP) LP
Signature:By: Avidity Capital Partners (GP) LLC, its general partner, By: /s/ Michael Gregory
Name/Title:Michael Gregory/Managing Member
Date:08/14/2025
Avidity Capital Partners (GP) LLC
Signature:/s/ Michael Gregory
Name/Title:Michael Gregory/Managing Member
Date:08/14/2025
Avidity Private Master Fund I LP
Signature:By: Avidity Capital Partners Fund (GP) LP, its general partner, By: Avidity Capital Partners (GP) LLC, its general partner, By: /s/ Michael Gregory
Name/Title:Michael Gregory/Managing Member
Date:08/14/2025
Michael Gregory
Signature:/s/ Michael Gregory
Name/Title:Michael Gregory
Date:08/14/2025

Comments accompanying signature: * Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. To the extent that "ownership of 5 percent or less of a class" was indicated in Item 5, such response only applies to the Reporting Person(s) that indicated elsewhere herein that it beneficially owns five percent (5%) or less of the class.
Exhibit Information

[Exhibit A - Joint Filing Agreement] [Exhibit B - Control Person Identification]

FAQ

How many IMUX shares does Avidity report owning?

The Avidity reporting persons disclose an aggregate position of 5,615,811 shares of Immunic (IMUX).

What percentage of IMUX does the Avidity group own?

The reported aggregate position represents 5.9% of the outstanding common stock.

Does any reporting person have sole voting or dispositive power over the IMUX shares?

No; the filing shows 0 shares of sole voting or dispositive power and reports only shared voting and dispositive power.

Are the shares held directly or on behalf of clients?

The filing states the securities are directly owned by advisory clients of Avidity Partners Management LP and that none of those clients may be deemed to beneficially own more than 5%.

Who signed the Schedule 13G/A for Avidity?

The filing is signed by Michael Gregory as Managing Member on behalf of the Avidity reporting entities.
Immunic Inc

NASDAQ:IMUX

IMUX Rankings

IMUX Latest News

IMUX Latest SEC Filings

IMUX Stock Data

85.63M
118.99M
1.31%
53.6%
9.97%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK